These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20233418)

  • 1. An integrative paradigm to impart quality to correlative science.
    Kalos M
    J Transl Med; 2010 Mar; 8():26. PubMed ID: 20233418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.
    Anderson BD; Adamson PC; Weiner SL; McCabe MS; Smith MA
    J Clin Oncol; 2004 Dec; 22(23):4846-50. PubMed ID: 15570088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design.
    Kansal AR; Trimmer J
    Syst Biol (Stevenage); 2005 Dec; 152(4):214-20. PubMed ID: 16986263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in T-cell therapy clinical trials.
    Lacey SF; Kalos M
    Cytotherapy; 2013 Jun; 15(6):632-40. PubMed ID: 23415917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing paradigm for prediction of development-limiting barriers and human drug toxicity.
    Sasseville VG; Lane JH; Kadambi VJ; Bouchard P; Lee FW; Balani SK; Miwa GT; Smith PF; Alden CL
    Chem Biol Interact; 2004 Nov; 150(1):9-25. PubMed ID: 15522258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
    Lewis RM; Cavagnaro J
    Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in early-phase trials: fundamental issues.
    Yee LM; Lively TG; McShane LM
    Bioanalysis; 2018 Jun; 10(12):933-944. PubMed ID: 29923753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradigms for adaptive statistical information designs: practical experiences and strategies.
    Wang SJ; Hung HM; O'Neill R
    Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Responsibilities of clinical pharmacology in the early phase of drug development].
    Kuhlmann J
    Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
    Lefer DJ; Bolli R
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.